There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Olin Janssen |
| Institution: | Maastricht University |
| Department: | Department of Psychiatry and Neuropsychology |
| Country: | |
| Proposed Analysis: | We will test the relation of demographic, lifestyle and comorbid variables with amyloid accumulation in subjects with normal cognition, SCD, MCI and dementia. The relation between amyloid accumulation and other AD biomarkers will also be assessed. We will build a prediction model to generate amyloid positivity screening scores on an individual level. Furthermore, we will assess the relation between amyloid positivity and rate of cognitive decline on several domains and test which demographic, lifestyle and comorbid variables modify this relationship in persons with normal cognition, SCD, MCI and dementia who have abnormal amyloid in CSF or on PET. |
| Additional Investigators | |
| Investigator's Name: | Willemijn Jansen |
| Proposed Analysis: | We will test the relation of demographic, lifestyle and comorbid variables with amyloid accumulation in subjects with normal cognition, SCD, MCI and dementia. The relation between amyloid accumulation and other AD biomarkers will also be assessed. We will build a prediction model to generate amyloid positivity screening scores on an individual level. Furthermore, we will assess the relation between amyloid positivity and rate of cognitive decline on several domains and test which demographic, lifestyle and comorbid variables modify this relationship in persons with normal cognition, SCD, MCI and dementia who have abnormal amyloid in CSF or on PET. |
| Investigator's Name: | Pieter Jelle Visser |
| Proposed Analysis: | We will test the relation of demographic, lifestyle and comorbid variables with amyloid accumulation in subjects with normal cognition, SCD, MCI and dementia. The relation between amyloid accumulation and other AD biomarkers will also be assessed. We will build a prediction model to generate amyloid positivity screening scores on an individual level. Furthermore, we will assess the relation between amyloid positivity and rate of cognitive decline on several domains and test which demographic, lifestyle and comorbid variables modify this relationship in persons with normal cognition, SCD, MCI and dementia who have abnormal amyloid in CSF or on PET. |
